These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 20200560

  • 21. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 22. NGF-withdrawal induces apoptosis in pancreatic beta cells in vitro.
    Pierucci D, Cicconi S, Bonini P, Ferrelli F, Pastore D, Matteucci C, Marselli L, Marchetti P, Ris F, Halban P, Oberholzer J, Federici M, Cozzolino F, Lauro R, Borboni P, Marlier LN.
    Diabetologia; 2001 Oct 01; 44(10):1281-95. PubMed ID: 11692177
    [Abstract] [Full Text] [Related]

  • 23. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling.
    Park SK, Sanders BG, Kline K.
    Breast Cancer Res Treat; 2010 Nov 01; 124(2):361-75. PubMed ID: 20157774
    [Abstract] [Full Text] [Related]

  • 24. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
    Shi YY, Small GW, Orlowski RZ.
    Breast Cancer Res Treat; 2006 Nov 01; 100(1):33-47. PubMed ID: 16807678
    [Abstract] [Full Text] [Related]

  • 25. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
    Zhao X, Qiu W, Kung J, Zhao X, Peng X, Yegappan M, Yen-Lieberman B, Hsi ED.
    Leuk Res; 2008 Feb 01; 32(2):275-85. PubMed ID: 17659339
    [Abstract] [Full Text] [Related]

  • 26. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
    Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC.
    Blood; 2003 Feb 15; 101(4):1530-4. PubMed ID: 12393500
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF, Yu LJ, Meng YF, Lv HY, Meng J, Song XN, Zhang JQ.
    Leuk Lymphoma; 2013 Mar 15; 54(3):607-18. PubMed ID: 22889356
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, Tassone P, Chauhan D, Hideshima T, Denis L, Richardson P, Munshi NC, Anderson KC.
    Cancer Res; 2004 Dec 01; 64(23):8746-53. PubMed ID: 15574786
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.
    Br J Haematol; 2007 Feb 01; 136(3):414-23. PubMed ID: 17173546
    [Abstract] [Full Text] [Related]

  • 39. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y, Wang LJ, He DH, Zhao Y, Wu WJ, Zheng GF, Han XY, Huang H, Yi Q, Cai Z.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):443-53. PubMed ID: 25305450
    [Abstract] [Full Text] [Related]

  • 40. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
    Neri P, Tassone P, Shammas M, Yasui H, Schipani E, Batchu RB, Blotta S, Prabhala R, Catley L, Hamasaki M, Hideshima T, Chauhan D, Jacob GS, Picker D, Venuta S, Anderson KC, Munshi NC.
    Leukemia; 2007 Dec 28; 21(12):2519-26. PubMed ID: 17882285
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.